Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | SY-1365 |
Synonyms | |
Therapy Description |
SY-1365 is a selective CDK7 inhibitor that induces apoptosis in tumor cells (PMID: 31064851). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SY-1365 | SY1365 | CDK7 Inhibitor 14 | SY-1365 is a selective CDK7 inhibitor that induces apoptosis in tumor cells (PMID: 31064851, PMID: 32150405). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | triple-receptor negative breast cancer | not applicable | SY-1365 | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, SY-1365 induced rapid apoptosis in triple-receptor negative breast cancer cells in culture, and resulted in tumor growth inhibition in patient-derived xenograft models (Proceedings of the AACR, Vol 58, April 2017, Abstract # 1151). | detail... |
Unknown unknown | Advanced Solid Tumor | not applicable | SY-1365 | Preclinical - Cell culture | Actionable | In a preclinical study, SY-1365 induced rapid apoptosis in a panel of solid tumor cell lines in culture, including breast, ovarian, colorectal, and lung cancer cells (Proceedings of the AACR, Vol 58, April 2017, Abstract # 1151). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03134638 | Phase I | Carboplatin + SY-1365 SY-1365 Fulvestrant + SY-1365 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | Terminated | USA | CAN | 1 |